Načítá se...
Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
Recent advances in the management of prostate cancer have shown considerable development with time and many novel therapeutic agents have been approved over the past years. For patients with metastatic castration-resistant prostate cancer (mCRPC), initially docetaxel was the standard chemotherapy bu...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications & Media Pvt Ltd
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3825997/ https://ncbi.nlm.nih.gov/pubmed/24250198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0976-500X.119704 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|